Zenas BioPharma, Inc.
ZBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 |
| % Growth | -90% | – | – |
| Gross Profit | -$0 | $0 | -$0 |
| % Margin | -2,682.8% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 |
| % Margin | -3,275% | -54.1% | – |
| Net Income | -$0 | -$0 | -$0 |
| % Margin | -3,139.8% | -74.2% | – |
| EPS Diluted | -3.76 | -0.97 | -3.11 |
| % Growth | -287.6% | 68.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 |